May 23, 2013
Antibody gets high marks for asthma
Asthma exacerbations decreased by 87% in patients treated with an investigational agent that targets the interleukin-4 (IL-4) receptor, results of a placebo-controlled phase II trial showed. Dupilumab was associated with an exacerbation rate of 6% compared with 44% in the placebo group. Measures of lung function and asthma control also improved significantly…